In adults with obesity and type 2 diabetes, bimagrumab reduces visceral fat by 36.1% and liver fat by 23.6% within 24 weeks, regardless of changes in calorie intake.
See the scientific wording
In adults with obesity and type 2 diabetes, administration of bimagrumab reduces visceral adipose tissue by approximately 36.1% and hepatic fat fraction by 23.6% within 24 weeks, independent of changes in caloric intake, indicating a direct effect on ectopic fat deposition.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman
The study found that a drug called bimagrumab shrunk dangerous belly and liver fat by over 20% in people with obesity and diabetes—even when they didn’t eat less—proving it works directly on fat inside organs.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Bimagrumab blocks specific receptors on muscle and fat cells, which stops signals that normally limit muscle growth and promote fat storage. This causes muscle to grow larger and fat cells to store less fat, especially in the belly and liver, without needing to eat less.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity and type 2 diabetes, bimagrumab reduces visceral fat by 36.1% and liver fat by 23.6% within 24 weeks, regardless of changes in calorie intake.
Mechanism
1 studyBimagrumab blocks signals that keep muscles small and fat cells full. This makes muscles grow bigger and fat cells store less fat, especially in the belly and liver, without changing how much a person eats.
Bimagrumab blocks specific receptors on muscle and fat cells, which stops signals that normally limit muscle growth and promote fat storage. This causes muscle to grow larger and fat cells to store less fat, especially in the belly and liver, without needing to eat less.
Bimagrumab binds with high affinity to ActRIIA and ActRIIB receptors on the surface of skeletal muscle and adipose tissue cells
Binding prevents activin ligands, including myostatin and activin A, from activating the receptors and triggering Smad2/3 phosphorylation
Inhibition of Smad2/3 signaling in skeletal muscle cells removes suppression of protein synthesis and myogenesis, leading to increased muscle mass
Inhibition of Smad2/3 signaling in adipocytes reduces lipid storage and adipogenesis, decreasing total fat mass and ectopic fat accumulation in visceral and hepatic tissues
Evidence from Studies
Supporting (1)
Community contributions welcome
370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms
The study found that a drug called bimagrumab shrunk dangerous belly and liver fat by over 20% in people with obesity and diabetes—even when they didn’t eat less—proving it works directly on fat inside organs.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab Trials on Visceral and Hepatic Fat Reduction in Obesity and Type 2 Diabetes
Population: Adults with obesity and type 2 diabetes; Intervention: Bimagrumab; Comparator: Placebo; Outcome: Change in visceral adipose tissue and hepatic fat fraction; Duration: 24 weeks; Inclusion: Only trials controlling for caloric intake.
Double-Blind, Placebo-Controlled Trial of Bimagrumab on Visceral and Hepatic Fat in Obesity and Type 2 Diabetes Over 24 Weeks
Population: Adults with obesity and type 2 diabetes; Intervention: Bimagrumab; Comparator: Placebo; Outcome: Change in visceral adipose tissue (MRI) and hepatic fat fraction (MRI spectroscopy); Duration: 24 weeks; Control: Caloric intake held constant via dietary monitoring.
Prospective Cohort Study of Bimagrumab Use and Changes in Ectopic Fat in Adults with Obesity and Type 2 Diabetes Over 24 Weeks
Population: Adults with obesity and type 2 diabetes prescribed bimagrumab; Comparator: Non-users matched for baseline characteristics; Outcome: Change in visceral adipose tissue and hepatic fat fraction; Duration: 24 weeks; Measurement: Caloric intake tracked via food diaries.
In Vitro Study of Bimagrumab on Adipocyte Lipid Accumulation and Hepatocyte Fat Deposition in Human Cell Lines
Population: Human adipocyte and hepatocyte cell lines; Intervention: Bimagrumab exposure; Comparator: Vehicle control; Outcome: Intracellular lipid content measured by Oil Red O staining and biochemical assays; Duration: 7–14 days.
Animal Model Study of Bimagrumab on Ectopic Fat Deposition in Diet-Induced Obese Mice with Induced Insulin Resistance
Population: Diet-induced obese mice with insulin resistance; Intervention: Bimagrumab; Comparator: Saline control; Outcome: Visceral and hepatic fat mass measured by MRI and histology; Duration: 24 weeks; Control: Caloric intake matched across groups.